Skip to main content

Table 1 Characteristics of the study cohort

From: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

 

No cancer detected n = 548

Diagnosed with cancer n = 192

Clinical characteristics

  

Age at venipuncture (years)

61 (58, 64)

61 (58, 64)

Total PSA (ng/ml)

4.21 (3.39, 5.55)

5.81 (4.07, 10.4)

Free PSA (ng/ml)

0.87 (0.66, 1.25)

0.83 (0.60, 1.35)

Intact PSA (ng/ml)

0.37 (0.28, 0.52)

0.43 (0.29, 0.73)

Human kallikrein 2 (ng/ml)

0.046 (0.030, 0.068)

0.076 (0.050, 0.128)

Tumor characteristics

  

Abnormal DRE

50 (9%)

76 (40%)

Biopsy Gleason score

  

   ≤6

 

152 (79%)

   7

 

33 (17%)

   ≥8

 

7 (4%)

  1. Data are median (interquartile range) or frequency (percentage). DRE, digital rectal examination; PSA, prostate specific antigen.